β-Peptide Conjugates: Syntheses and CD and NMR Investigations of β/α-Chimeric Peptides, of a DPA-β-Decapeptide, and of a PEGylated β-Heptapeptide
β3‐Peptides consisting of six, seven, and ten homologated proteinogenic amino acid residues have been attached to an α‐heptapeptide (all d‐amino acid residues; 4), to a hexaethylene glycol chain (PEGylation; 5c), and to dipicolinic acid (DPA derivative 6), respectively. The conjugation of the β‐pept...
Saved in:
Published in: | Helvetica chimica acta Vol. 92; no. 12; pp. 2698 - 2721 |
---|---|
Main Authors: | , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Zürich
WILEY-VCH Verlag
01-12-2009
WILEY‐VCH Verlag |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | β3‐Peptides consisting of six, seven, and ten homologated proteinogenic amino acid residues have been attached to an α‐heptapeptide (all d‐amino acid residues; 4), to a hexaethylene glycol chain (PEGylation; 5c), and to dipicolinic acid (DPA derivative 6), respectively. The conjugation of the β‐peptides with the second component was carried out through the N‐termini in all three cases. According to NMR analysis (CD3OH solutions), the (M)‐314‐helical structure of the β‐peptidic segments was unscathed in all three chimeric compounds (Figs. 2, 4, and 5). The α‐peptidic section of the α/β‐peptide was unstructured, and so was the oligoethylene glycol chain in the PEGylated compound. Thus, neither does the appendage influence the β‐peptidic secondary structure, nor does the latter cause any order in the attached oligomers to be observed by this method of analysis. A similar conclusion may be drawn from CD spectra (Figs. 1, 3, and 5). These results bode well for the development of delivery systems involving β‐peptides. |
---|---|
Bibliography: | ArticleID:HLCA200900325 ark:/67375/WNG-P04PNHJH-C istex:90A50EB9A1159B167C484C16B52C35A2338E7609 ETH Dissertation No. 17209 (2007), financed by Part of the Ph.D. Thesis of J. S. Postdoctoral Research Fellow at ETH‐Zürich (2004–2006), financed by the ETH Dissertation No. 14298 (2001). (No. 200020‐100182), and by New Zealand Foundation for Research Science and Technology Postdoctoral Research Fellow at ETH‐Zürich (2004–2007), financed by the (No. SWSS0401). Swiss National Science Foundation Novartis Pharma AG R. I. M. Deutsche Forschungsgemeinschaft (No. 200020‐109065). by the Basel. |
ISSN: | 0018-019X 1522-2675 |
DOI: | 10.1002/hlca.200900325 |